Plasmablastic lymphoma: case report
Main Article Content
Keywords
Hypercalcemia, Bone, Fractures, Fractures Non-Hodgkin, Plasmablastic Lymphoma
Abstract
Background: Plasmablastic lymphoma is a high grade non-Hodgkin lymphoma. It is described in patients with HIV infection, post-transplant and advanced age. It appears in the fourth decade of life and the oral cavity is the most common site of affection. Its neoplastic cells express markers of plasma cells such as CD138, CD38. In its pathogenesis the Epstein-Barr virus has been implicated. The most challenging consideration in the differential diagnosis is with multiple myeloma, since the morphological and immunophenotypic characteristics of these two entities are very similar. Treatment with EPOCH (etoposide, epirubicin, vincristine, cyclophosphamide and prednisone) associated with antiretroviral treatment is the most effective option, improving survival to 17 months.
Case report: Male of 35 years with HIV and symptoms of organic dysfunction associated with myeloma. Protein electrophoresis and bone marrow aspiration were performed, ruling out multiple myeloma. Continuing with the diagnostic approach and with suspicion of bone neoplasia, a bone biopsy was performed with report of plasmablastic lymphoma CD 138+ and Ki-67 80%, Epstein-Barr positive. He received chemotherapy with EPOCH, with a six-month survival.
Conclusions: The presence of organic dysfunction related to myeloma motivated the search for said pathology and the presence of plasmablastic lymphoma was determined; clinical, biochemical, immunohistochemical, and radiographic correlation are essential for correct diagnosis.
References
1. Akce M, Chang E, Haeri M, Perez M, Finch CJ, Udden MM, et al. Bortezomib, ifosfamide, carboplatin, and etoposide in a patient with HIV-negative relapsed plasmablastic lymphoma. Case Rep Hematol. 2016;2016:3598547.
2. Fernández-Álvarez R, Sancho JM, Ribera JM. Plasmablastic lymphoma. Med Clin (Barc). 2016;147(9):399-404.
3. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125(15):2323-31.
4. Morscio J, Dierickx D, Nijs J, Verhoef G, Bittoun E, Vanoeteren X, et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients:single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol. 2014;38(7):875-86.
5. Folk GS, Abbondanzo SL, Childers EL, Foss RD. Plasmablastic lymphoma:a clinicopathologic correlation. Ann Diagn Pathol. 2006;10(1):8-12.
6. Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, et al. Human immunodeficiency virus-associated plasmablastic lymphoma:poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118(21):5270-7.
7. Fever DH. Research letters. J Trop Pediatr. 2003;49(5):308-10.
8. Castillo JJ, Chávez JC, Hernández-Ilizaliturri FJ, Montes-Moreno S. CD20-negative diffuse large B-cell lymphomas:biology and emerging therapeutic options. Expert Rev Hematol. 2015;8(3):343-54.
9. Dasanu CA, Bauer F, Codreanu I, Padmanabhan P, Rampurwala M. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol. 2013;31(3):164-6.
10. Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169(3):352-5.
11. Yan M, Dong Z, Zhao F, Chauncey T, Deauna-Limayo D, Wang-Rodriguez J, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93(1):77-80.
12. Advances in Hematology. Retracted:Plasmablastic lymphoma:a review of current knowledge and future directions. Adv Hematol. 2016;2016:9742148.
13. Lin L, Zhang X, Dong M, Li L, Wang X, Zhang L, et al. Human immunodeficiency virus-negative plasmablastic lymphoma:a case report and literature review. Medicine (Balt). 2017;96:e6171.
14. Liu M, Liu B, Liu B, Wang Q, Ding L, Xia C, et al. Human immunodeficiency virus-negative plasmablastic lymphoma:a comprehensive analysis of 114 cases. Oncol Rep. 2015;33(4):1615-20.
15. Marrero WD, Cruz-Chacón A, Castillo C, Cabanillas F. Successful use of bortezomib-lenalidomide combination as treatment for a patient with plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18(7):e275-7.
16. Guerrero-García TA, Mogollón RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma:a glimpse of hope for a hard-to-treat disease. Leuk Res. 2017;62:12-6.
17. Sharma D, Khurana N, Narula V, Mohanty S. Plasmablastic lymphoma presenting as gingival growth in a HIV positive patient:a case report. J Oral Maxillofac Surg Med Pathol. 2016;28(4):366-9.
18. Ma H, Wei MH, Qin HM, Wang GY, Hu ZC. Long-term survival of primary intracranial plasmablastic lymphoma:case report and review of the literature. World Neurosurg. 2017;97:750.e5-10.
19. Oishi N, Bagán JV, Javier K, Zapater E. Head and neck lymphomas in HIV patients:a clinical perspective. Int Arch Otorhinolaryngol. 2017;21(4):399-407.
20. Rafei H, El-Bahesh E, Finianos A, Liu M-LL, Schechter GP. Plasmablastic lymphoma:case report of prolonged survival of an advanced human immunodeficiency patient and literature review. Case Rep Hematol. 2017;2017:9561013.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.